ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / DMRA
NKTR (20) KARD (46) OMER (41) AAPG (45) ⌘ Pro Terminal →

Damora Therapeutics Inc. (DMRA) — RQD Stock Rating Cockpit

$21.60 +0.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $21.58

Damora Therapeutics Inc. (DMRA) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $1.33B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DMRA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DMRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Damora Therapeutics Inc. (NASDAQ: DMRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $21.60 (+0.51% 1D, market cap $1.33B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, DMRA ranks #590 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DMRA compare to NKTR and KARD in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DMRA carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NKTR (Nektar Therapeutics) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B) and KARD (Kardigan Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $1.32B). Among the 5-stock peer group, DMRA leads on earnings multiple (N/A) while DMRA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DMRA?
▼

Per DMRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001800315), Damora Therapeutics Inc. generated $590.4M in revenue (+847.3% YoY), -$209.8M in net income, and -$6.7M in free cash flow against $260.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $21.58 (-0.10%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510035
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (9)Whales (6)SEC (10)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-10.4% Base Target
$40 Bull$19 Base$15 Bear
📬 FREE DMRA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DMRA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
🔍 WHY DMRA SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+9/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
27
Grade E$18.56+11.4% Next Q
Q2 (-2Q)
30
Grade E$20.67+6.2% Next Q
Q3 (-1Q)
32
Grade E$21.96-1.6% Next Q
Current
35
Grade D-$21.60-8.5% Hist 90D α
Trajectory: E (27) → D- (35)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DMRA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DMRA currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($23.18) and Max Pain ($22.68) forces dealer call-delta covering toward $40.25.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DMRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DMRA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 35%NO 65%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
49.630 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE50% OF RANGE
L: $5$21.60H: $38
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 9 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 17 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on DMRA

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (45)

-35.0% ROIC with 42.0% gross margin and -0.49% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (27)

9/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like DMRA
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DMRA)

  • ✓Walkthrough of DMRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
DMRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -16.70%📐 HORIZONTAL RANGE
2026-11-03O $22.01H $22.01L $21.49C $21.60VOL 339.5K
RES: $40.03SUP: $17.34SMA50: $23.18SMA200: $25.63
$36.13$31.00$25.88$20.76$15.64RES $40.03SUP $17.34$21.602026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DMRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DMRA Butterfly Map → + Track DMRA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +847.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on DMRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DMRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DMRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DMRA)

Health Care Rank #590 of 1015 ⚔️ NKTR vs DMRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DMRA vs. NKTR, KARD, OMER, AAPG)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Damora Therapeutics Inc. (DMRA) ranks #590 by composite RQD confidence (35/100, grade D-) and #318 by equity capitalization ($1.33B). Within this direct 5-issuer industry benchmark cohort, DMRA leads on earnings valuation at N/A trailing P/E, while DMRA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. KARD currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with DMRA at 35/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
DMRA ACTIVE
Damora Therapeutics Inc.
D- 35/100 — — -35.0% +0.51% $1.33B Benchmark Subject
NKTR
Nektar Therapeutics
E 20/100 — 96.0% -35.0% -4.94% $1.33B /nktr-vs-dmra →
KARD
Kardigan Inc.
D 46/100 — — — +0.57% $1.32B /kard-vs-dmra →
OMER
Omeros Corporation
D- 41/100 — — -35.0% -3.31% $1.33B /omer-vs-dmra →
AAPG
Ascentage Pharma Group International American Depository Shares
D 45/100 — — — -6.20% $1.35B /aapg-vs-dmra →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001800315 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Damora Therapeutics Inc. (DMRA) reported GAAP revenue of $590.4M (+847.3% vs. FY2024 revenue of $62.3M , and +428.4% cumulative change since FY2023) , GAAP net income of -$209.8M, operating cash flow of -$6.7M, and free cash flow of -$6.7M (+63.9% YoY). On the balance sheet, DMRA closed FY2025 with $260.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $590.4M -$209.8M -$6.7M -$6.7M $260.5M —
FY2024 (FY) 2024-12-31 $62.3M -$21.4M -$18.6M -$18.6M $17.1M —
FY2023 (FY) 2023-12-31 $111.7M -$38.3M -$36.9M -$36.9M — —

3. DMRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DMRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Damora Therapeutics Inc. (NASDAQ: DMRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $21.60 (+0.51% 1D, market cap $1.33B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, DMRA ranks #590 in composite RQD confidence.

How does DMRA compare to NKTR and KARD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DMRA carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NKTR (Nektar Therapeutics) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $1.33B) and KARD (Kardigan Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $1.32B). Among the 5-stock peer group, DMRA leads on earnings multiple (N/A) while DMRA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DMRA?

Per DMRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001800315), Damora Therapeutics Inc. generated $590.4M in revenue (+847.3% YoY), -$209.8M in net income, and -$6.7M in free cash flow against $260.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DMRA trading relative to its 50-day, 200-day, and 52-week technical levels?

DMRA last traded at $21.60 (+0.51% on volume of 497,331 shares), positioning the stock -6.82% below its 50-day simple moving average ($23.18) and -15.72% below its 200-day simple moving average ($25.63). Across its 52-week range of $4.95 to $38.33, DMRA sits at the 49.9% percentile with a 14-day RSI of 49.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($18.90 to $24.30).

Direct Sub-Reports: DMRA RQD Cockpit DMRA 12M Forecast DMRA Earnings & Move DMRA Dividends & DRIP DMRA Insiders & 13F DMRA Whale Options DMRA Profit Sankey DMRA News & Why
ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ SEC XBRL & RQD VERIFIED

DMRA — Damora Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Damora Therapeutics Inc. (DMRA) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $21.60 (+0.51% 1D, market capitalization $1.33B).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -0.49%.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Damora Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The profile lists a market capitalization of $1.4B. Reported revenue in the SEC financials is — for each period shown.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Damora Therapeutics Inc. (DMRA) reported $590.4M in annual revenue (up from $62.3M in FY2024, +847.3% YoY) and -$209.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($111.7M revenue, -$38.3M net income) through FY2025, DMRA scaled operating cash flow to -$6.7M and free cash flow to -$6.7M, backed by $260.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -0.49% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $4.95 – $38.33 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers, downstream customers, and sector correlation data are therefore — For a prospective investor, the key second-order watch item is the anticipated widening of losses noted in the risk-watch news item, combined with the cash balance's dependence on continued financing or operating progress. Because the supply-chain graph is empty, no bottleneck mapping can be sourced from this dataset.

  • Key Question #1: Can DMRA sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $590.4M and free cash flow of -$6.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is DMRA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

DMRA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Damora Therapeutics Inc. (DMRA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DMRA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DMRA Bull vs. Bear Conversation Board — What's Your Call at $21.60?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DMRA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on DMRA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $27.51 (+28.0%)
📌 Pinned Debate

Cash rose to $257.6M in FY 2025 from $14.2M in FY 2024, giving the company a larger liquidity cushion against its operating losses.

Picked up a starter position in DMRA in my $100K Virtual Cash book at $21.49. Cash rose to $257.6M in FY 2025 from $14.2M in FY 2024, giving the company a larger liquidity cushion against its operating losses.. Trading inside a $3.90–$38.33 52-week range with -0.49% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

SectorRotator 🐂 BULL

@QuantViper Agree on the RQD 35/100 quality, though with 1.0 beta I'm scaling in with half-size at $21.49 and keeping dry powder in case we test $19.99.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $16.98 (-21.0%)
Spot @ $21.49

With $0.0M revenue, ROIC of -35%, and an operating loss of -$210.9M in FY 2025, the company is not generating returns that support its

Fading this rally in DMRA at $21.49. With $0.0M revenue, ROIC of -35%, and an operating loss of -$210.9M in FY 2025, the company is not generating returns that support its $1.36B market value.. With a beta of 1.0 and the stock sitting at $21.49 (52-wk range $3.90–$38.33), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%